|SMmDSHm

8e :Cz A!4AQ^/Q| P ---:!-B: yi3h)hJ)3T tk !DX?n ,tsx &|mQQ &OPOF(PO@ 3`6 uFBF9SFBxS x}\7B^%7|O *8^ n_dn@8. ?Tq|T]T f& scU= nk]\]`z ** m(\Uu\ I~x#:@V+:~@ ]Sg]/RS~] cE}^( (# ~Nms ;hy/ 2 GKg}:}R{@J ;ao ZUIpM_} RBfWZo YY gKbgta SH6oX=69.

|SMmDSHm

8e :Cz A!4AQ^/Q| P ---:!-B: yi3h)hJ)3T tk !DX?n ,tsx &|mQQ &OPOF(PO@ 3`6 uFBF9SFBxS x}\7B^%7|O *8^ n_dn@8. ?Tq|T]T f& scU= nk]\]`z ** m(\Uu\ I~x#:@V+:~@ ]Sg]/RS~] cE}^( (# ~Nms ;hy/ 2 GKg}:}R{@J ;ao ZUIpM_} RBfWZo YY gKbgta SH6oX=69.

ccY5c]@7
77y{3y{ `Mfp n] A|M|zrZw
}*8y0
}-p%wj:%;-1
R;;Lw;;
}-p%wj:%;-1
9%
}-p%wj:%;-1
p=p :^
}-p%wj:%;-1
_L_ {|+
}-p%wj:%;-1
hQ f,3
}-p%wj:%;-1
r/r v{o
}-p%wj:%;-1
X1X #Q*4Q y#RE fBF*m
}-p%wj:%;-1
?b(F8a[%0X 8J(g8(E h53u!! 7IrYfmImxY3:
}-p%wj:%;-1
ZN #JJᵃ
}-p%wj:%;-1
}$} bg
}-p%wj:%;-1
HMH p77
}-p%wj:%;-1
r/r v{o
}-p%wj:%;-1
Bs GbbUzbb6
}-p%wj:%;-1
K$K mm PNly 4&ff8f=u
}-p%wj:%;-1
iP&xPf`
}-p%wj:%;-1
^Ahh55 eZNeVyZy2ezw
}-p%wj:%;-1
^Ahh55 eZNeVyZy2ezw
}-p%wj:%;-1
;]ih\\ [6l){060_)2db
}-p%wj:%;-1
P(P _J% g]y GQG ahh
}-p%wj:%;-1
^Ahh55 eZNeVyZy2ezw
}-p%wj:%;-1
IoI ;$_
}-p%wj:%;-1
GeG So%Wo
}-p%wj:%;-1
_~QDo~m k)kM=LfZEg A?w?ncw)5?A
}-p%wj:%;-1
Y^F^s fps:jfVfj
}-p%wj:%;-1
Rqq9mW%WVN ^uo/e fL\,f))fSfTL
}-p%wj:%;-1
m#UKwqwKp EiE ;WpO22
}-p%wj:%;-1
$m py=pF uQ?6?
}-p%wj:%;-1
,4 5j @W:D:
}-p%wj:%;-1
prP\ 5)O*O
}-p%wj:%;-1
F)}~FBw zzA#A
}-p%wj:%;-1
ES p:B:J|J
}-p%wj:%;-1
FO |L**
}-p%wj:%;-1
g~ +Bss
}-p%wj:%;-1
-- ]FII
}-p%wj:%;-1
Tn 8TC8{7T
}-p%wj:%;-1
DB ,l+
}-p%wj:%;-1
FC d&&
}-p%wj:%;-1
b` uI*
}-p%wj:%;-1
C7/Q B??
}-p%wj:%;-1
~L in}(} ?a{V2{qD=i/{a 9^qKR9I]e^v\
}-p%wj:%;-1
:C +Uoka lLhl b^tPt
}-p%wj:%;-1
,q6j6 fBA) On~T7r;!J7n~
}-p%wj:%;-1
~H k#t P3=SZ (3=7@e
}-p%wj:%;-1
~H k#t P3=SZ (3=7@e
}-p%wj:%;-1
~H k#t P3=SZ (3=7@e
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
fmmO$2$
}-p%wj:%;-1
FO |L**
}-p%wj:%;-1
]D 9PAAA
}-p%wj:%;-1
F)}~FBw zzA#A
}-p%wj:%;-1
[i[ ZzB3B
}-p%wj:%;-1
bo 07T^^
}-p%wj:%;-1
{x 4WFdN i$I
}-p%wj:%;-1
YL f7kS+ _Q\
}-p%wj:%;-1
O]s,:Bo,B J0
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
dG Iye gep]A- jF1A
}-p%wj:%;-1
Rk ~Y&Y
}-p%wj:%;-1
ES p:B:J|J
}-p%wj:%;-1
HP=P=H=
}-p%wj:%;-1
jB !Y_Y
}-p%wj:%;-1
L&T&&
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI
}-p%wj:%;-1
x/+!s C:*ApI

xb /I N@V@DG #_#^

fAmgen collaboration; BeiGene has China commercial rights. PEnsem collaboration; BeiGene has global rights. {DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. {Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. &Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. eAmgen collaboration; BeiGene has development and commercialization rights in China. fIn combination with Zanubrutinib. 8May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login